Navigation Links
Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients

SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- BSD Medical Corp. announced today that the results of a 340 patient randomized Phase III clinical trial testing the benefit of adding hyperthermia therapy to chemotherapy were presented at the annual American Society of Clinical Oncology (ASCO) conference underway in Chicago, Illinois. According to the results of this clinical study, which was conducted at nine major European cancer treatment institutions and at Duke University Medical Center in the USA, both disease-free survival time and local progression free survival time for patients with locally advanced, high-grade soft tissue sarcomas nearly doubled when hyperthermia therapy was added to chemotherapy, as compared to patients who received chemotherapy alone.

The patients enrolled in this clinical study were very ill, with high-grade (II/III) soft tissue sarcomas and were at significant risk of local failure and metastasis. The patients were randomly assigned to receive either chemotherapy alone or chemotherapy combined with hyperthermia therapy. The patient characteristics were well balanced between these two groups. Their treatments were administered in 4 cycles every 3 weeks before and after surgery and radiation therapy. For patients who received both hyperthermia therapy and chemotherapy the median disease free survival was 31.7 months, compared to 16.2 months for those who received chemotherapy alone (p=0.004), a 95% increase. The median local progression free survival rate was estimated at 45.3 months for patients who received chemotherapy plus hyperthermia therapy, compared to 23.7 months for patients who received chemotherapy alone (p=0.01), a 91% increase.

The study was conducted under the direction of the European Society of Hyperthermic Oncology (ESHO RHT-95) and the European Organization for Research and Treatment of Cancer (EORTC 62961). Rolf Issels, MD PhD of the Munich U niversity Medical School in Germany, was the principal investigator. Duke University was a participant in the international study listed on the National Cancer Institute's website at http://www.cancer.gov/clinicaltrials/EORTC-62961 under the NCI number NCT00003052.

All hyperthermia treatments performed in the study were conducted using BSD-2000 hyperthermia systems developed and produced by BSD Medical Corp. The BSD-2000 hyperthermia therapy system non-invasively delivers precision focused hyperthermia therapy to cancerous tumors, including tumors located deep in the body. The BSD-2000 is a recipient of the Frost and Sullivan Technology Innovation of the Year Award for cancer therapy devices.

About BSD Medical

BSD Medical Corp. is the leading developer of systems used to deliver hyperthermia therapy for the treatment of cancer. Hyperthermia therapy is used to kill cancer directly and increase the effectiveness of companion radiation treatments. Research has also shown promising results from the use of hyperthermia therapy in combination with chemotherapy, and for tumor reduction prior to surgery. For further information visit BSD Medical's website at http://www.BSDMedical.com or BSD's patient website at http://www.treatwithheat.com. Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Hyrum A. Mead of BSD Medical Corporation, +1-801-972-5555, fax,+1-801-972-5930, investor@bsdmc.com

Web site: http://www.BSDMedical.com/http://www.treatwithheat.com/http://www.cancer.gov/clinicaltrials/EORTC-62961/

Ticker Symbol: (AMEX:BSM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
2. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
3. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
4. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
5. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a ... diagnostic tests and pathology services, announced today the acceptance ... United States and Canadian Academy ... in San Antonio, Texas . ... from the Company,s extensive experience in molecular thyroid testing, ...
(Date:2/27/2017)... 27, 2017  International Biophysics Corporation, a global medical device ... announced a 34% revenue growth in 2016 when compared to ... sales.  This growth was fueled by its AffloVest® sales in ... the expansion of its global sales of surgical product lines. ... "As we enter our 25 th year in delivering ...
(Date:2/27/2017)... 2017   Vitasome ® Labs , Inc. ... its groundbreaking new liposome technology. Whereas vitamins lose on ... digestion per Physician,s Desk Reference , Vitasome , ... nutritional waste and are scientifically formulated to: ... Improve bioavailability with a vastly higher absorption ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail ... addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , ... had 800 customers and 2,250 RCEs at the time of acquisition. In the ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is ... Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads ... founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):